Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet.
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Theoretical concentration curve at a half-life of 168 h. Pure pharmacokinetic model — not a dosing recommendation.
Open in PK tool →Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
These cofactors relate to the peptide class, not to a specific use. No recommendation, no dosing.
Science only, no sales. Unsubscribe anytime.
We store your email only for the newsletter. Unsubscribe anytime. Privacy